Product Images Losartan Potassium

This is a description of a medication called Losartan Potassium 25mg produced by NuCare Pharmaceuticals, Inc. The National Drug Code (NDC) for this drug is 68071-5159-9. The package includes tablets and a warning advising that it should be kept out of the reach of children. The drug label should be consulted for a full list of ingredients. The package also includes a lot number, manufacturing NDC, and exp date. The package also states that the medication should be stored at a controlled temperature of 68-77°F.*

The text is describing the effectiveness of two medications, Atenolol and Losartan, in reducing the risk of a primary endpoint in patients. It provides a graph showing the percentage of patients with the primary endpoint over a study period of 66 months, along with an adjusted risk reduction of 13% with a significance value of p=0.021.*

This is a graph showing the percentage of patients who experienced fatal or non-fatal stroke while taking either Atenolol or Losartan over a 66-month study period.*

The text provided is a table presenting the results of a study comparing Losartan and Atenolol in reducing the risk of primary composite stroke (fatal/non-fatal) in patients with different characteristics such as age, gender, race, history of cardiovascular disease, etc. The table shows the number of events, event rate, hazard ratio, and confidence interval. Therefore, it is not possible to generate a "useful" description without additional information about the study design, methodology, and purpose.*

This appears to be a graph that shows the risk reduction percentage of Losartan compared to a placebo medication. Losartan appears to have a 16.1% risk reduction rate, with a p-value of 0.0225. The graph measures the time in months, with measurements taken at 0, 12, 24, 36, 48.*